ReviewWorld journal of clinical oncology2020
Nephrotoxicity in cancer treatment: An overview.
Review in World journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Pregnancy after cancer: FIGO Best practice advice.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Guideline
- Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review.International journal of molecular sciences · 2021Pooled it
- Trial
- Chronic Kidney Disease in Children Within Five Years After Ifosfamide Chemotherapy for Childhood Cancer: A Dutch Pediatric Oncology Cohort Study.Cancer medicine · 2026Article
- The Unusual Coexistence of Chronic Lymphocytic Leukemia, Dengue Fever, and Acute Kidney Injury: A Case Report.Clinical case reports · 2026Article
- Complexed rifampicin with iron mitigates doxorubicin-induced nephrotoxicity.BMC pharmacology & toxicology · 2026Article
- The renoprotective effect of d-limonene against cisplatin-induced acute kidney injury: targeting Nrf2/HO-1 and NLRP-3 inflammasome signaling pathways.Molecular and cellular biochemistry · 2026Article
- The protective effect of ambroxol against cyclophosphamide-induced acute kidney injury involves Nrf2/HO-1 signaling upregulation and suppression of oxidative and inflammatory damage.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A systems-level machine learning approach uncovers therapeutic targets in clear cell renal cell carcinoma.npj drug discovery · 2026Article
- Curcumin treatment attenuates methotrexate-induced nephrotoxicity in rats by inhibiting inflammation and fibrosis.Journal of molecular histology · 2026Article
- Treatment-Refractory Hypothyroidism due to Proteinuria During Combined Immune Checkpoint and Tyrosine Kinase Inhibitor Therapy - A Case Report.Clinical medicine insights. Endocrinology and diabetes · 2026Article
- Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy.Hepatology forum · 2026Article
- Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization andJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Article
- Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy-A case report.Cancer chemotherapy and pharmacology · 2025Article
- Riociguat Alleviates Cisplatin-Caused Kidney Injury by Suppressing Oxidative Stress and Inflammation.Biology · 2025Article
- Chronic Diseases Related to Diet and/or Nutrition in Patients With an Ileostomy - A Scoping Review.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025Article
- Review
- Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancer.Breast cancer research and treatment · 2025Article
- Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies.Cancer medicine · 2025Article
- Case report: Nephrotic syndrome induced by Lenvatinib treatment in a patient with von Hippel-Lindau syndrome.BMC nephrology · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticancer drug nephrotoxicity is an important and increasing adverse drug event that limits the efficacy of cancer treatment. The kidney is an important elimination pathway for many antineoplastic drugs and their metabolites, which occurs by glomerular filtration and tubular secretion. Chemotherapeutic agents, both conventional cytotoxic agents and molecularly targeted agents, can affect any segment of the nephron including its microvasculature, leading to many clinical manifestations such as proteinuria, hypertension, electrolyte disturbances, glomerulopathy, acute and chronic interstitial nephritis, acute kidney injury and at times chronic kidney disease. The clinician should be alert to recognize several factors that may maximize renal dysfunction and contribute to the increased incidence of nephrotoxicity associated with these drugs, such as intravascular volume depletion, the associated use of nonchemotherapeutic nephrotoxic drugs (analgesics, antibiotics, proton pump inhibitors, and bone-targeted therapies), radiographic ionic contrast media or radiation therapy, urinary tract obstruction, and intrinsic renal disease. Identification of patients at higher risk for nephrotoxicity may allow the prevention or at least reduction in the development and severity of this adverse effect. Therefore, the aim of this brief review is to provide currently available evidences on oncologic drug-related nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.